Highlight
Circulating tumor DNA (ctDNA) provides a sensitive method to detect measurable residual disease (MRD) in large B-cell lymphoma (LBCL) patients post-therapy, potentially improving relapse risk stratification beyond standard positron emission tomography (PET) imaging. While PET remains central to response assessment, it lacks the ability to identify molecular-only residual disease that ctDNA can reveal. Clinical implementation of ctDNA-based MRD monitoring is promising but requires further validation and standardized protocols to optimize its impact on therapeutic decision-making.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
